IL 12 TM
Alternative Names: IL-12-TMLatest Information Update: 10 Oct 2024
Price :
$50 *
At a glance
- Originator Arovella Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer T cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Aug 2024 Preclinical trials in Solid tumours in Australia (IV) prior to August 2024 (Arovella Therapeutics pipeline, August 2024)
- 31 Jul 2024 Interim pharmacodynamics data from a preclinical studies in Solid tumours released by Arovella Therapeutics
- 31 Jan 2024 Arovella Therapeutics in-licenses cytokine technology from University of North Carolina (Arovella Therapeutics, website, August 2024)